Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim collaboration

Boehringer Ingelheim and 4-Antibody are to collaborate on the development of fully human therapeutic antibodies for various disease indications

Boehringer Ingelheim and 4-Antibody are to collaborate on a long-term project to discover and develop fully human therapeutic antibodies for targets in various disease indications. 

Swiss-based 4-Antibody will use its proprietary and unencumbered Hu-PAC and Retrocyte Display technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody will receive payments of up to €177.5m (CHF 266m) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones. Further financial details were not disclosed. 

Dr Ulf Grawunder, co-founder and CSO of 4-Antibody, said: "This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody's fully human antibody discovery and engineering platforms to create valuable potential new drug candidates. Our unique and unencumbered technology capabilities allow the efficient generation of novel or improved fully human antibodies against any target class for our collaboration partners and for our own clinical development pipeline." 

4-Antibody owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen granted patents worldwide. It has headquarters in Basel, with a subsidiary in Jena, Germany. 

17th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics